TABLE 1.
Comparison of EBOV PsV entry-inhibitory activities of HP-HSA modified with different concentrations of HPa
| HP concn (mM) | Modification rate (%) |
Zaire PsV |
Sudan PsV |
|||
|---|---|---|---|---|---|---|
| Lys | Arg | EC50 (μM) | EC90 (μM) | EC50 (μM) | EC90 (μM) | |
| 0 | 0 | 0 | >20 | >20 | >20 | >20 |
| 2.5 | 14.4 | 20.2 | >20 | >20 | >20 | >20 |
| 5 | 42.5 | 41.4 | 8.17 ± 1.22 | >20 | 10.63 ± 8.94 | >20 |
| 12 | 71.5 | 58.6 | 0.643 ± 0.232 | >20 | 2.33 ± 0.54 | >20 |
| 25 | 88.3 | 78.1 | 0.087 ± 0.030 | 5.256 ± 0.803 | 0.172 ± 0.038 | 6.186 ± 0.424 |
| 36 | 95.9 | 91.0 | 0.073 ± 0.019 | 1.970 ± 0.235 | 0.105 ± 0.010 | 4.663 ± 0.068 |
| 48 | 100 | 95.6 | 0.096 ± 0.002 | 1.413 ± 0.086 | 0.093 ± 0.007 | 4.433 ± 0.396 |
| 60 | 100 | 100 | 0.087 ± 0.011 | 1.126 ± 0.079 | 0.088 ± 0.020 | 2.790 ± 0.539 |
a
Each sample was tested in triplicate. Data are presented as the mean ± standard deviation.